+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      The Effect of Apomorphine and Ergocriptine on the Release of MSH by the Pars intermedia of Rana pipiens


      S. Karger AG

      Dopamine receptors, Apomorphine, Ergocriptine, MSH, Pars intermedia

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          In an attempt to further characterize the nature of the innervation controlling melanophore-stimulating hormone (MSH) release from the pars intermedia (PI), pellets containing either apomorphine or ergocriptine were implanted in contact with the PI of the frog, and the effect on the animal’s coloration was observed. Frogs with apomorphine implants exhibited skin pallor for several hours and those with ergocriptine implants were pallid for a few days. Hypophysectomized (HX) frogs which had been darkened with MSH regained their pallor no sooner when given an injection of apomorphine than with the vehicle. However, intact dark frogs lightened when injected with apomorphine. Frogs darkened by autotransplantation of the PI to the dorsal lymph sac were lightened by an injection of apomorphine. Frogs lightened by an ergocriptine implant on the PI and then darkened by MSH did not lighten sooner than HX frogs given an injection of MSH. Ergocriptine-containing pellets implanted in the thigh took longer to produce the same effect than those implanted in contact with the PI. Since apomorphine is known to stimulate dopamine receptors in the central nervous system, and there is some evidence that ergocriptine does also, the above evidence supports the hypothesis that dopamine receptors are present in the PI.

          Related collections

          Author and article information

          S. Karger AG
          20 March 2008
          : 19
          : 4
          : 363-376
          Department of Zoology and Entomology, Colorado State University, Fort Collins, Colo.
          122457 Neuroendocrinology 1975;19:363–376
          © 1975 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 14


          Comment on this article